Kazuhisa Nakashima
Overview
Explore the profile of Kazuhisa Nakashima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
3376
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murakami M, Miyata Y, Nakashima K, Abe M, Nishimura J, Wada M, et al.
Int J Clin Oncol
. 2024 Nov;
30(1):27-39.
PMID: 39570460
Background: Olanzapine is an atypical antipsychotic drug used for chemotherapy-induced nausea and vomiting. It is particularly effective in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy (HEC). However,...
2.
Nakashima K, Harashima S, Kaneko R, Tanaka R, Abe M, Wada M, et al.
Int J Clin Oncol
. 2024 Nov;
30(1):17-26.
PMID: 39531096
Background: A standardized multi-day antiemetic regimen for multi-day chemotherapy remains elusive. This systematic review evaluated the efficacy and safety of multi-day antiemetic regimens in patients undergoing multi-day intravenous chemotherapy. Methods:...
3.
Nakashima K, Yokomizo A, Murakami M, Okita K, Wada M, Iino K, et al.
Int J Clin Oncol
. 2024 Oct;
29(12):1785-1794.
PMID: 39417943
Background: Palonosetron, a second-generation 5-HT receptor antagonist (5-HTRA), is more effective than first-generation 5-HTRA. Several studies have investigated whether dexamethasone (DEX), when combined with palonosetron as a 5-HTRA, can be...
4.
Nakashima K, Kodama H, Murakami H, Takahashi T, Kawakado K, Yanagawa T, et al.
Respir Investig
. 2024 Oct;
62(6):1137-1141.
PMID: 39366122
Background: There is a dearth of studies on the efficacy and safety of the tyrosine kinase inhibitors osimertinib (OSI) and gefitinib (GEF) in treating epidermal growth factor receptor (EGFR) mutation-positive...
5.
Yokomizo A, Nakashima K, Iba A, Okita K, Wada M, Iino K, et al.
Int J Clin Oncol
. 2024 Sep;
29(11):1632-1640.
PMID: 39340704
Background: Chemotherapy-induced nausea and vomiting (CINV) are common side effects, classified according to timing and severity. Conventional agents such as dexamethasone are effective but have various side effects. For moderately...
6.
Wada S, Ideno H, Nakashima K, Komatsu K, Demura N, Tomonari H, et al.
Sci Rep
. 2024 Sep;
14(1):20771.
PMID: 39237663
G9a is a histone methyltransferase that catalyzes the methylation of histone 3 lysine 9 (H3K9), which is involved in the regulation of gene expression. We had previously reported that G9a...
7.
Komatsu K, Ideno H, Nakashima K, Udagawa N, Kobayashi Y, Kimura H, et al.
FASEB J
. 2024 Jul;
38(13):e23779.
PMID: 38967255
Epigenetic modifications affect cell differentiation via transcriptional regulation. G9a/EHMT2 is an important epigenetic modifier that catalyzes the methylation of histone 3 lysine 9 (H3K9) and interacts with various nuclear proteins....
8.
Kono K, Nakashima K, Tsubata Y, Amano Y, Kawakado K, Yanagawa T, et al.
Thorac Cancer
. 2024 Jul;
15(22):1714-1717.
PMID: 38956899
A 61-year-old man presented to our hospital with a chief complaint of chronic cough. He was diagnosed with lung squamous cell carcinoma at clinical stage cT2aN3M1a. He received chemotherapy up...
9.
Yagishita S, Yamanaka Y, Kurata T, Watanabe K, Hosomi Y, Horinouchi H, et al.
Clin Pharmacol Ther
. 2024 Jun;
116(4):1042-1051.
PMID: 38887810
Pembrolizumab is a major treatment for recurrent or advanced non-small-cell lung cancer (NSCLC). However, data on its use and pharmacokinetics (PK) in older patients are limited. This open-label, multicenter, observational...
10.
Nishioka N, Imai H, Endo M, Notsu A, Doshita K, Igawa S, et al.
Target Oncol
. 2024 Apr;
19(3):423-433.
PMID: 38613731
Background: Although osimertinib is a promising therapeutic agent for advanced epidermal growth factor receptor (EGFR) mutation-positive lung cancer, the incidence of pneumonitis is particularly high among Japanese patients receiving the...